Crossmark

Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain

Crossref DOI link: https://doi.org/10.1016/j.medcle.2015.11.026

Published Print: 2015-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

López, M. Fernanda

Mingot, María Eva

Valcárcel, David

Vicente García, Vicente

Perrin, Allison

Campos Tapias, Ignasi
License Information

Text and Data Mining valid from 2015-05-01
More Information

This article is maintained by: Elsevier

Article Title: Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain

Journal Title: Medicina Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcle.2015.11.026

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.medcli.2013.11.035

Content Type: article

Copyright: Copyright © 2013 Elsevier España, S.L.U. All rights reserved.